The Phase I Gene Therapy Study for Fabry Disease is looking to recruit interested patients. This is a first-in-human study for the treatment of Fabry disease.
Full Press release link Idorsia Pharmaceuticals (www.idorsia.com), a Swiss biotech company, is developing lucerastat, a new oral therapy for patients with Fabry Disease. The Phase 3 clinical study MODIFY has just enrolled its first patients and will investigate the use of lucerastat monotherapy for the treatment of adult patients with Fabry disease, irrespective of their […]
The Canadian Fabry Association (CFA) is conducting a short survey with patients living with Fabry disease and their caregivers. If you qualify and successfully complete the survey, you will have the option to enter in a draw to win a CAN $150 gift certificate to Keg Steakhouse. You may complete the survey only once. Your […]
We are committed to improving the lives of those who live with and are affected by Fabry disease in Canada.
Subscribe error, please review your email address.Close
You're now subscribed, thank you!Close
There was a problem with your submission. Please check the field(s) with red label below.Close
Your message has been sent. We'll get back to you soon!Close